Is ADIL or ADMA more undervalued in 2026?

CirclFi compares Adial Pharmaceuticals, Inc (ADIL) and ADMA Biologics Inc (ADMA) using 13 institutional-grade valuation models. ADIL has a Quality of Company score of 4.4/10 while ADMA scores 9.1/10.

Which is a better buy — ADIL or ADMA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ADIL and ADMA valuations compare?

ADIL at $2.53 and ADMA at $7.93 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ADIL vs ADMA Valuation Comparison 2026 — Intrinsic Value Analysis

ADIL

Biotechnology

Adial Pharmaceuticals, Inc

Quality

4.4

out of 10

Value Trap

SAFE

Price

$2.53

Last close

Models

7/13

Active

ADMA

Biotechnology

ADMA Biologics Inc

Quality

9.1

out of 10

Value Trap

SAFE

Price

$7.93

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	ADIL Fair Value	ADIL Upside	ADMA Fair Value	ADMA Upside
Bayesian DCF	Intrinsic	$1.85	-27.0%	$1.30	-83.6%
Earnings Power Value	Intrinsic	—	—	$5.87	-26.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.33	-78.5%	$8.09	+2.0%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ADIL vs ADMA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ADIL vs ADMA — Which Stock Is More Undervalued?

ADMA scores higher with a 9.1/10 quality rating vs ADIL's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Adial Pharmaceuticals, Inc (ADIL) and ADMA Biologics Inc (ADMA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ADIL currently trades at $2.53 with a QOC of 4.4/10, while ADMA trades at $7.93 with a QOC of 9.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).